The American journal of medicine
The most recent articles from:
Am. J. Med.
-
Excess mortality remains the cornerstone concern despite dual antiplatelet therapy (DAPT) after acute coronary syndrome. Some data suggest that shorter periods than 12 months of DAPT diminish bleeding risks yet still provide adequate vascular protection and improving survival. However, the precise timing of deaths after acute coronary syndrome has not been mapped in many studies. This knowledge may be critical for defining optimal treatment duration. ⋯ Focusing on mortality reduction, this large data set may support a shorter than 12 months' duration of DAPT.